CD8A and tuberculosis: Thus, these results collectively suggested that BCG-Nanocage induced similar levels of anti-TB effector functions of CD4+ and CD8+ αβ T cells, which is comparable with live BCG bacteria, and induced stronger Vγ2Vδ2 T cell responses than live BCG bacteria did.